グラム陰性菌感染症(Gram-Negative Bacterial Infections):世界の治験レビュー(2014年下半期版)

◆英語タイトル:Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014
◆商品コード:GDHC2444CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2014年11月30日
◆ページ数:123
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥535,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥802,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるグラム陰性菌感染症(Gram-Negative Bacterial Infections) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - グラム陰性菌感染症(Gram-Negative Bacterial Infections)
  - 当レポートの概要
・グラム陰性菌感染症(Gram-Negative Bacterial Infections):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014

Summary

GlobalData’s clinical trial report, “Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014″ provides data on the Gram-Negative Bacterial Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gram-Negative Bacterial Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gram-Negative Bacterial Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Gram-Negative Bacterial Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Gram-Negative Bacterial Infections 25
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Gram-Negative Bacterial Infections Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Gram-Negative Bacterial Infections 37
Nov 05, 2014: The Medicines Company Announces First Patient Enrollment in Phase 3 Studies of CARBAVANCE in Development for the Treatment of Serious Bacterial Infections Due to Gram-Negative Bacteria 37
Oct 09, 2014: Novel Siderophore Cephalosporin S-649266 Pre-Clinical Results Suggest Potent Activity Against Multidrug-Resistant Gram-Negative Pathogens 38
Sep 08, 2014: Shionogi Presents Pre-Clinical and Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens 39
Clinical Trial Profiles 40
Clinical Trial Overview of Top Companies 40
GlaxoSmithKline plc 40
Clinical Trial Overview of GlaxoSmithKline plc 40
Sanofi 51
Clinical Trial Overview of Sanofi 51
Novartis AG 58
Clinical Trial Overview of Novartis AG 58
Merck & Co., Inc. 61
Clinical Trial Overview of Merck & Co., Inc. 61
Gilead Sciences, Inc. 63
Clinical Trial Overview of Gilead Sciences, Inc. 63
AstraZeneca PLC 65
Clinical Trial Overview of AstraZeneca PLC 65
Prokarium Ltd. 67
Clinical Trial Overview of Prokarium Ltd. 67
Pfizer Inc. 68
Clinical Trial Overview of Pfizer Inc. 68
Actavis plc 69
Clinical Trial Overview of Actavis plc 69
Clinical Trial Overview of Top Institutes / Government 70
The National Institute of Allergy and Infectious Diseases 70
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 70
National Taiwan University Hospital 72
Clinical Trial Overview of National Taiwan University Hospital 72
University of Pittsburgh 74
Clinical Trial Overview of University of Pittsburgh 74
International Vaccine Institute 76
Clinical Trial Overview of International Vaccine Institute 76
Radboud University 77
Clinical Trial Overview of Radboud University 77
University of Oxford 78
Clinical Trial Overview of University of Oxford 78
Centers for Disease Control and Prevention 79
Clinical Trial Overview of Centers for Disease Control and Prevention 79
Tehran University of Medical Sciences 80
Clinical Trial Overview of Tehran University of Medical Sciences 80
Eunice Kennedy Shriver National Institute of Child Health and Human Development 81
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 81
University of California, San Francisco 82
Clinical Trial Overview of University of California, San Francisco 82
Five Key Clinical Profiles 83
Appendix 121
Abbreviations 121
Definitions 121
Research Methodology 122
Secondary Research 122
About GlobalData 123
Contact Us 123
Disclaimer 123
Source 123

List of Tables
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Region, 2014* 7
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Gram-Negative Bacterial Infections Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Gram-Negative Bacterial Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Gram-Negative Bacterial Infections Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Gram-Negative Bacterial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 40
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 51
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 58
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 61
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014* 63
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 65
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Prokarium Ltd., 2014* 67
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 68
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Actavis plc, 2014* 69
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 70
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 72
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 74
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by International Vaccine Institute, 2014* 76
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Radboud University, 2014* 77
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2014* 78
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014* 79
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 80
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 81
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 82

List of Figures
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Gram-Negative Bacterial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 122

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[グラム陰性菌感染症(Gram-Negative Bacterial Infections):世界の治験レビュー(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆